Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Estimating absolute risk of lung cancer for never-smoking individuals is important to inform lung cancer screening programs. To integrate data on environmental tobacco smoke (ETS), a known lung cancer risk factor, with a polygenic risk score (PRS) that captures overall genetic susceptibility, to estimate the absolute risk of lung adenocarcinoma (LUAD) among never-smokers in Taiwan. The analyses were conducted in never-smoking women in the Taiwan Genetic Epidemiology Study of Lung Adenocarcinoma, a case-control study. Participants were recruited between September 17, 2002, and March 30, 2011. Data analysis was performed from January 17 to July 15, 2022. A PRS was derived using 25 genetic variants that achieved genome-wide significance (P < 5 × 10-8) in a recent genome-wide association study, and ETS was defined as never exposed, exposed at home or at work, and exposed at home and at work. The Individualized Coherent Absolute Risk Estimator software was used to estimate the lifetime absolute risk of LUAD in never-smoking women aged 40 years over a projected 40-year span among the controls by using the relative risk estimates for the PRS and ETS exposures, as well as age-specific lung cancer incidence rates for never-smokers in Taiwan. Likelihood ratio tests were conducted to assess an additive interaction between the PRS and ETS exposure. Data were obtained on 1024 women with LUAD (mean [SD] age, 59.6 [11.4] years, 47.9% ever exposed to ETS at home, and 19.5% ever exposed to ETS at work) and 1024 controls (mean [SD] age, 58.9 [11.0] years, 37.0% ever exposed to ETS at home, and 14.3% ever exposed to ETS at work). The overall average lifetime 40-year absolute risk of LUAD estimated using PRS alone was 2.5% (range, 0.6%-10.3%) among women never exposed to ETS. When integrating both ETS and PRS data, the estimated absolute risk was 3.7% (range, 0.6%-14.5%) for women exposed to ETS at home or work and 5.3% (range, 1.2%-12.1%) for women exposed to ETS at home and work. A super-additive interaction between ETS and the PRS (P = 6.5 × 10-4 for interaction) was identified. This study found differences in absolute risk of LUAD attributed to genetic susceptibility according to levels of ETS exposure in never-smoking women. Future studies are warranted to integrate these findings in expanded risk models for LUAD.
Identifiants
pubmed: 37955902
pii: 2811767
doi: 10.1001/jamanetworkopen.2023.39254
pmc: PMC10644212
doi:
Substances chimiques
Tobacco Smoke Pollution
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2339254Références
Am J Public Health. 1989 Oct;79(10):1381-4
pubmed: 2782507
Am J Hum Genet. 2009 Nov;85(5):679-91
pubmed: 19836008
Lung Cancer (Auckl). 2019 Sep 30;10:107-124
pubmed: 31686936
PLoS Genet. 2013 Mar;9(3):e1003348
pubmed: 23555274
Nat Genet. 2010 Oct;42(10):893-6
pubmed: 20871597
Blood. 2010 Sep 16;116(11):1899-907
pubmed: 20538793
Angew Chem Int Ed Engl. 2010 Oct 4;49(41):7405-21
pubmed: 20821774
Nat Commun. 2023 May 26;14(1):3043
pubmed: 37236969
Cancer. 2008 Jul 15;113(2):396-404
pubmed: 18484588
Nat Genet. 2013 Apr;45(4):422-7, 427e1-2
pubmed: 23535734
Eur Respir J. 2015 May;45(5):1403-14
pubmed: 25657019
Stat Med. 2011 May 10;30(10):1090-104
pubmed: 21337591
Hum Mol Genet. 2017 Jan 15;26(2):454-465
pubmed: 28025329
PLoS Genet. 2010 Aug 05;6(8):
pubmed: 20700438
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278
Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):452-459
pubmed: 31848206
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Chin J Cancer. 2017 Feb 8;36(1):20
pubmed: 28179026
PLoS Med. 2014 Dec 02;11(12):e1001764
pubmed: 25460915
Int J Cancer. 2015 Jul 15;137(2):311-9
pubmed: 25516442
J Natl Cancer Inst. 2010 Jul 7;102(13):959-71
pubmed: 20548021
PLoS One. 2020 Feb 5;15(2):e0228198
pubmed: 32023287
Hum Mol Genet. 2016 Feb 1;25(3):620-9
pubmed: 26732429
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Genet. 2008 Dec;40(12):1404-6
pubmed: 18978790
N Engl J Med. 1993 Nov 18;329(21):1543-6
pubmed: 8413477
Nat Genet. 2012 Dec;44(12):1330-5
pubmed: 23143601
Cancer Causes Control. 2013 Mar;24(3):567-76
pubmed: 22729933
Oncotarget. 2018 Apr 27;9(32):22559-22570
pubmed: 29854298
Cancer Res. 2014 Aug 1;74(15):4090-8
pubmed: 24853549
Int J Cancer. 2012 Jul 15;131(2):265-75
pubmed: 22322343